Browse TNFSF4

Summary
SymbolTNFSF4
Nametumor necrosis factor (ligand) superfamily, member 4
Aliases OX-40L; gp34; CD252; TXGP1; tax-transcriptionally activated glycoprotein 1, 34kD; CD134L; OX4OL; CD134 ligan ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type II membrane protein.
Domain -
Function

Cytokine that binds to TNFRSF4. Co-stimulates T-cell proliferation and cytokine production.

> Gene Ontology
 
Biological Process GO:0000018 regulation of DNA recombination
GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0002200 somatic diversification of immune receptors
GO:0002204 somatic recombination of immunoglobulin genes involved in immune response
GO:0002208 somatic diversification of immunoglobulins involved in immune response
GO:0002215 defense response to nematode
GO:0002237 response to molecule of bacterial origin
GO:0002250 adaptive immune response
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002287 alpha-beta T cell activation involved in immune response
GO:0002292 T cell differentiation involved in immune response
GO:0002293 alpha-beta T cell differentiation involved in immune response
GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response
GO:0002312 B cell activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002367 cytokine production involved in immune response
GO:0002369 T cell cytokine production
GO:0002377 immunoglobulin production
GO:0002381 immunoglobulin production involved in immunoglobulin mediated immune response
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002456 T cell mediated immunity
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002521 leukocyte differentiation
GO:0002526 acute inflammatory response
GO:0002562 somatic diversification of immune receptors via germline recombination within a single locus
GO:0002637 regulation of immunoglobulin production
GO:0002639 positive regulation of immunoglobulin production
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002702 positive regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002705 positive regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002708 positive regulation of lymphocyte mediated immunity
GO:0002709 regulation of T cell mediated immunity
GO:0002711 positive regulation of T cell mediated immunity
GO:0002712 regulation of B cell mediated immunity
GO:0002714 positive regulation of B cell mediated immunity
GO:0002718 regulation of cytokine production involved in immune response
GO:0002720 positive regulation of cytokine production involved in immune response
GO:0002724 regulation of T cell cytokine production
GO:0002726 positive regulation of T cell cytokine production
GO:0002819 regulation of adaptive immune response
GO:0002820 negative regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002823 negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002825 regulation of T-helper 1 type immune response
GO:0002826 negative regulation of T-helper 1 type immune response
GO:0002828 regulation of type 2 immune response
GO:0002830 positive regulation of type 2 immune response
GO:0002889 regulation of immunoglobulin mediated immune response
GO:0002891 positive regulation of immunoglobulin mediated immune response
GO:0006066 alcohol metabolic process
GO:0006310 DNA recombination
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0008202 steroid metabolic process
GO:0008203 cholesterol metabolic process
GO:0009306 protein secretion
GO:0009615 response to virus
GO:0010035 response to inorganic substance
GO:0016064 immunoglobulin mediated immune response
GO:0016125 sterol metabolic process
GO:0016444 somatic cell DNA recombination
GO:0016445 somatic diversification of immunoglobulins
GO:0016447 somatic recombination of immunoglobulin gene segments
GO:0019724 B cell mediated immunity
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030098 lymphocyte differentiation
GO:0030217 T cell differentiation
GO:0031294 lymphocyte costimulation
GO:0031295 T cell costimulation
GO:0031349 positive regulation of defense response
GO:0032103 positive regulation of response to external stimulus
GO:0032496 response to lipopolysaccharide
GO:0032602 chemokine production
GO:0032609 interferon-gamma production
GO:0032613 interleukin-10 production
GO:0032615 interleukin-12 production
GO:0032616 interleukin-13 production
GO:0032620 interleukin-17 production
GO:0032623 interleukin-2 production
GO:0032633 interleukin-4 production
GO:0032635 interleukin-6 production
GO:0032649 regulation of interferon-gamma production
GO:0032653 regulation of interleukin-10 production
GO:0032655 regulation of interleukin-12 production
GO:0032656 regulation of interleukin-13 production
GO:0032660 regulation of interleukin-17 production
GO:0032663 regulation of interleukin-2 production
GO:0032673 regulation of interleukin-4 production
GO:0032675 regulation of interleukin-6 production
GO:0032689 negative regulation of interferon-gamma production
GO:0032700 negative regulation of interleukin-17 production
GO:0032729 positive regulation of interferon-gamma production
GO:0032733 positive regulation of interleukin-10 production
GO:0032735 positive regulation of interleukin-12 production
GO:0032736 positive regulation of interleukin-13 production
GO:0032743 positive regulation of interleukin-2 production
GO:0032753 positive regulation of interleukin-4 production
GO:0032755 positive regulation of interleukin-6 production
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0034612 response to tumor necrosis factor
GO:0034694 response to prostaglandin
GO:0034695 response to prostaglandin E
GO:0035708 interleukin-4-dependent isotype switching to IgE isotypes
GO:0035709 memory T cell activation
GO:0035710 CD4-positive, alpha-beta T cell activation
GO:0035712 T-helper 2 cell activation
GO:0035713 response to nitrogen dioxide
GO:0035714 cellular response to nitrogen dioxide
GO:0035783 CD4-positive, alpha-beta T cell costimulation
GO:0042088 T-helper 1 type immune response
GO:0042092 type 2 immune response
GO:0042093 T-helper cell differentiation
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042104 positive regulation of activated T cell proliferation
GO:0042110 T cell activation
GO:0042113 B cell activation
GO:0042129 regulation of T cell proliferation
GO:0043367 CD4-positive, alpha-beta T cell differentiation
GO:0043370 regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043371 negative regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043372 positive regulation of CD4-positive, alpha-beta T cell differentiation
GO:0043379 memory T cell differentiation
GO:0043380 regulation of memory T cell differentiation
GO:0043382 positive regulation of memory T cell differentiation
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity
GO:0045063 T-helper 1 cell differentiation
GO:0045064 T-helper 2 cell differentiation
GO:0045066 regulatory T cell differentiation
GO:0045190 isotype switching
GO:0045191 regulation of isotype switching
GO:0045580 regulation of T cell differentiation
GO:0045581 negative regulation of T cell differentiation
GO:0045582 positive regulation of T cell differentiation
GO:0045589 regulation of regulatory T cell differentiation
GO:0045590 negative regulation of regulatory T cell differentiation
GO:0045619 regulation of lymphocyte differentiation
GO:0045620 negative regulation of lymphocyte differentiation
GO:0045621 positive regulation of lymphocyte differentiation
GO:0045622 regulation of T-helper cell differentiation
GO:0045623 negative regulation of T-helper cell differentiation
GO:0045624 positive regulation of T-helper cell differentiation
GO:0045625 regulation of T-helper 1 cell differentiation
GO:0045626 negative regulation of T-helper 1 cell differentiation
GO:0045628 regulation of T-helper 2 cell differentiation
GO:0045630 positive regulation of T-helper 2 cell differentiation
GO:0045785 positive regulation of cell adhesion
GO:0045830 positive regulation of isotype switching
GO:0045911 positive regulation of DNA recombination
GO:0046006 regulation of activated T cell proliferation
GO:0046631 alpha-beta T cell activation
GO:0046632 alpha-beta T cell differentiation
GO:0046633 alpha-beta T cell proliferation
GO:0046634 regulation of alpha-beta T cell activation
GO:0046635 positive regulation of alpha-beta T cell activation
GO:0046636 negative regulation of alpha-beta T cell activation
GO:0046637 regulation of alpha-beta T cell differentiation
GO:0046638 positive regulation of alpha-beta T cell differentiation
GO:0046639 negative regulation of alpha-beta T cell differentiation
GO:0046640 regulation of alpha-beta T cell proliferation
GO:0046641 positive regulation of alpha-beta T cell proliferation
GO:0046651 lymphocyte proliferation
GO:0048289 isotype switching to IgE isotypes
GO:0048293 regulation of isotype switching to IgE isotypes
GO:0048295 positive regulation of isotype switching to IgE isotypes
GO:0048305 immunoglobulin secretion
GO:0050663 cytokine secretion
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050707 regulation of cytokine secretion
GO:0050708 regulation of protein secretion
GO:0050709 negative regulation of protein secretion
GO:0050710 negative regulation of cytokine secretion
GO:0050714 positive regulation of protein secretion
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050777 negative regulation of immune response
GO:0050798 activated T cell proliferation
GO:0050863 regulation of T cell activation
GO:0050864 regulation of B cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050868 negative regulation of T cell activation
GO:0050870 positive regulation of T cell activation
GO:0050871 positive regulation of B cell activation
GO:0051023 regulation of immunoglobulin secretion
GO:0051024 positive regulation of immunoglobulin secretion
GO:0051047 positive regulation of secretion
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051052 regulation of DNA metabolic process
GO:0051054 positive regulation of DNA metabolic process
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051222 positive regulation of protein transport
GO:0051224 negative regulation of protein transport
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071216 cellular response to biotic stimulus
GO:0071219 cellular response to molecule of bacterial origin
GO:0071222 cellular response to lipopolysaccharide
GO:0071241 cellular response to inorganic substance
GO:0071356 cellular response to tumor necrosis factor
GO:0071379 cellular response to prostaglandin stimulus
GO:0071380 cellular response to prostaglandin E stimulus
GO:0071396 cellular response to lipid
GO:0071593 lymphocyte aggregation
GO:0071954 chemokine (C-C motif) ligand 11 production
GO:0098542 defense response to other organism
GO:1900279 regulation of CD4-positive, alpha-beta T cell costimulation
GO:1900281 positive regulation of CD4-positive, alpha-beta T cell costimulation
GO:1901615 organic hydroxy compound metabolic process
GO:1901654 response to ketone
GO:1901655 cellular response to ketone
GO:1902105 regulation of leukocyte differentiation
GO:1902106 negative regulation of leukocyte differentiation
GO:1902107 positive regulation of leukocyte differentiation
GO:1902652 secondary alcohol metabolic process
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903038 negative regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:1903531 negative regulation of secretion by cell
GO:1903532 positive regulation of secretion by cell
GO:1903706 regulation of hemopoiesis
GO:1903707 negative regulation of hemopoiesis
GO:1903708 positive regulation of hemopoiesis
GO:1904950 negative regulation of establishment of protein localization
GO:1904951 positive regulation of establishment of protein localization
GO:2000514 regulation of CD4-positive, alpha-beta T cell activation
GO:2000515 negative regulation of CD4-positive, alpha-beta T cell activation
GO:2000516 positive regulation of CD4-positive, alpha-beta T cell activation
GO:2000523 regulation of T cell costimulation
GO:2000525 positive regulation of T cell costimulation
GO:2000567 regulation of memory T cell activation
GO:2000568 positive regulation of memory T cell activation
GO:2000569 regulation of T-helper 2 cell activation
GO:2000570 positive regulation of T-helper 2 cell activation
GO:2000571 regulation of interleukin-4-dependent isotype switching to IgE isotypes
GO:2000572 positive regulation of interleukin-4-dependent isotype switching to IgE isotypes
Molecular Function GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005164 tumor necrosis factor receptor binding
GO:0032813 tumor necrosis factor receptor superfamily binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-5668541: TNFR2 non-canonical NF-kB pathway
R-HSA-5669034: TNFs bind their physiological receptors
Summary
SymbolTNFSF4
Nametumor necrosis factor (ligand) superfamily, member 4
Aliases OX-40L; gp34; CD252; TXGP1; tax-transcriptionally activated glycoprotein 1, 34kD; CD134L; OX4OL; CD134 ligan ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TNFSF4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TNFSF4 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25744203GlioblastomaInhibit immunity (T cell function)Taken together, these results suggest that glioblastoma may cooperate with Treg cells via OX40L, thereby enhancing IL-10 production. IL-10 in turn generates the immunosuppressive microenvironment. Such pro-tumor effects caused by Treg cells may be enhanced under hypoxic conditions.
29321210Acute Myeloid LeukemiaPromote immunity (T/NK cell function)The Immune Checkpoint Modulator OX40 and Its Ligand OX40L in NK-Cell Immunosurveillance and Acute Myeloid Leukemia. We also demonstrate that pNKC differentially express OX40L, depending on the protocol used for their generation. OX40L signaling promoted NK-cell activation, cytokine production, and cytotoxicity, and disruption of OX40-OX40L interaction impaired pNKC reactivity against primary AML cells.
27364122Melanoma; Colorectal carcinomaPromote immunity (T cell function)Among these costimulators, locally secreted Fc-OX40L provided superior priming of antigen-specific CD8(+) T cells, compared with combinations with OX40 antibodies or vaccine alone. A cell-based vaccine cosecreting gp96-Ig and Fc-OX40L led to even more pronounced tumor control, complete tumor rejection, and increased tumor antigen-specific T-cell proliferation, including in tumor-infiltrating lymphocytes, as compared with combinations of gp96-Ig vaccine and OX40 antibodies, in mice with established melanoma or colorectal carcinoma.
24957461Ovarian Dermoid Cyst with MelanomaPromote immunity (T cell function); essential for immunotherapyOX40L/OX40 interactions between DCs and Teff and/or Treg are critical for priming effective and therapeutic antitumour responses.
Summary
SymbolTNFSF4
Nametumor necrosis factor (ligand) superfamily, member 4
Aliases OX-40L; gp34; CD252; TXGP1; tax-transcriptionally activated glycoprotein 1, 34kD; CD134L; OX4OL; CD134 ligan ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TNFSF4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTNFSF4
Nametumor necrosis factor (ligand) superfamily, member 4
Aliases OX-40L; gp34; CD252; TXGP1; tax-transcriptionally activated glycoprotein 1, 34kD; CD134L; OX4OL; CD134 ligan ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TNFSF4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6240.0839
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.2530.735
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.890.11
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4020.268
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1540.886
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.7160.577
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3610.428
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.1360.897
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.7090.5
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1450.159
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.9970.0701
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.060.77
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TNFSF4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTNFSF4
Nametumor necrosis factor (ligand) superfamily, member 4
Aliases OX-40L; gp34; CD252; TXGP1; tax-transcriptionally activated glycoprotein 1, 34kD; CD134L; OX4OL; CD134 ligan ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TNFSF4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTNFSF4
Nametumor necrosis factor (ligand) superfamily, member 4
Aliases OX-40L; gp34; CD252; TXGP1; tax-transcriptionally activated glycoprotein 1, 34kD; CD134L; OX4OL; CD134 ligan ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TNFSF4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TNFSF4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTNFSF4
Nametumor necrosis factor (ligand) superfamily, member 4
Aliases OX-40L; gp34; CD252; TXGP1; tax-transcriptionally activated glycoprotein 1, 34kD; CD134L; OX4OL; CD134 ligan ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TNFSF4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTNFSF4
Nametumor necrosis factor (ligand) superfamily, member 4
Aliases OX-40L; gp34; CD252; TXGP1; tax-transcriptionally activated glycoprotein 1, 34kD; CD134L; OX4OL; CD134 ligan ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TNFSF4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTNFSF4
Nametumor necrosis factor (ligand) superfamily, member 4
Aliases OX-40L; gp34; CD252; TXGP1; tax-transcriptionally activated glycoprotein 1, 34kD; CD134L; OX4OL; CD134 ligan ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TNFSF4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTNFSF4
Nametumor necrosis factor (ligand) superfamily, member 4
Aliases OX-40L; gp34; CD252; TXGP1; tax-transcriptionally activated glycoprotein 1, 34kD; CD134L; OX4OL; CD134 ligan ......
Chromosomal Location1q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TNFSF4 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.